
CLAIMS


1. A compound of Formula (I):



(I);


or a hydrate, solvate, or pharmaceutically acceptable salt thereof, wherein:


R_1 is (a) C_8-C_{16} polycyclic cycloalkyl optionally substituted by one or more **R_6**,

(b) benzofuranyl or dihydrobenzofuranyl, wherein the benzofuranyl or dihydrobenzofuranyl is optionally substituted by one or more **R_6**;

(c) ;

(d) ;

(e) 



(f) hexahydroindacenyl;

R3 is H, methyl, or ethyl, wherein the methyl or ethyl is optionally substituted with one or more **R7**;

R4 is H, C_1-C_6 alkyl, -$(CH_2)_{0-3}$-(C_3-C_6 cycloalkyl), or -$(CH_2)_{0-3}$-C_5-C_6 aryl;

R6 is C_1-C_6 alkyl, C_2-C_6 alkenyl, C_1-C_6 alkoxy, C_3-C_8 cycloalkyl, halo, oxo, -OH, -CN, -NH_2, -NH(C_1-C_6 alkyl), -N(C_1-C_6 alkyl)$_2$, -CH_2F, -CHF_2, or -CF_3;

R7 is –OR_8, C_5-C_{10} aryl, or 5- to 10- membered heteroaryl, wherein the C_5-C_{10} aryl or 5- to 10-membered heteroaryl is optionally substituted by one or more **R7s**, wherein each **R7s** is

independently C_1-C_6 alkyl, C_1-C_6 alkoxy, 5- to 10-membered heteroaryl, halo, -OH, -CN, -$(CH_2)_{0-3}$-NH_2, -$(CH_2)_{0-3}$-$NH(C_1$-C_6 alkyl), -$(CH_2)_{0-3}$-$N(C_1$-C_6 alkyl)$_2$, -CH_2F, -CHF_2, or -CF_3; and


R_8 is C_1-C_6 alkyl or 5- to 7-membered heterocycloalkyl, wherein the C_1-C_6 alkyl or 5- to 7-membered heterocycloalkyl is optionally substituted by one or more **R_7**s.

2. The compound of claim 1, wherein **R_1** is:

(a) C_8-C_{16} polycyclic cycloalkyl substituted by one or more C_1-C_6 alkyl, C_2-C_6 alkenyl, C_1-C_6 alkoxy, C_3-C_8 cycloalkyl, halo, oxo, -OH, -CN, -NH_2, -$NH(C_1$-C_6 alkyl), -$N(C_1$-C_6 alkyl)$_2$, -CH_2F, -CHF_2, or -CF_3; or



(b) hexahydroindacenyl.


3. The compound of claim 1, wherein **R_1** is



.

4. The compound of claim 1, wherein **R_3** is methyl or ethyl, wherein the methyl or ethyl is optionally substituted with one or more –OR_8, C_5-C_{10} aryl, or 5- to 10- membered heteroaryl.

5. The compound of claim 1, wherein **R_3** is methyl substituted with one or more 5- to 10-membered heteroaryl, wherein the 5- to 10-membered heteroaryl is optionally substituted with one or more C_1-C_6 alkyl, C_1-C_6 alkoxy, halo, -CN, -$(CH_2)_{0-3}$-$N(C_1$-C_6 alkyl)$_2$, or -CF_3.


6. The compound of claim 1, wherein **R_3** is 
,

,
,
,







7. The compound of claim 1, wherein **R_4** is H.

8. The compound of claim 1, wherein **R_4** is C_1-C_6 alkyl, -$(CH_2)_{0-3}$-(C_3-C_6 cycloalkyl), or -$(CH_2)_{0-3}$-C_5-C_6 aryl.


9. The compound of claim 1, wherein **R_4** is methyl, ethyl, propyl, or butyl, 








10. The compound of claim 1, wherein at least one **R**$_7$ is 5- to 10-membered heteroaryl optionally substituted by one or more halo, -OH, -CN, -$(CH_2)_{0-3}$-NH_2, -$(CH_2)_{0-3}$-NH(C_1-C_6 alkyl), -$(CH_2)_{0-3}$-N(C_1-C_6 alkyl)$_2$, -CH_2F, -CHF_2, or -CF_3.


11. The compound of claim 1, being of Formula (Ia), (Ib), (II), (IIa), (IIb), (III), (IIIa), (IIIb), (IV), (IVa), (IVb), (V), (Va), (Vb), (VI), (VIa), (VIb), VII), (VIIa), (VIIb), (VIII), (VIIIa), (VIIIb), (IX), (IXa), (IXb), (X), (Xa), or (Xb):



(Ia);



(Ib);


(II);



(IIa);


(IIb);



(III);




(IIIa);




(IIIb);




(IV);




(IVa);




(IVb);




(V);




(Va);




(Vb);




(VI);




(VIa);




(VIb);




(VII);




(VIIa);




(VIIb);




(VIII);




(VIIIa);




(VIIIb);




(IX);




(IXa);




(IXb);



(X);










(Xa);


















(Xb);








or a hydrate, solvate, or pharmaceutically acceptable salt thereof.








12. A compound selected from Compound Nos. 1-8, 10-52, 55, 57-86, 88-117, 119-121, 123-128 and 130 and pharmaceutically acceptable salts thereof:







Compound No.	Structure	Name
1		Ethyl 2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}acetate
2		Ethyl 2-{[(2,6-difluorophenyl)carbamoyl]oxy}acetate
3		Ethyl 2-{[(2,6-dichlorophenyl)carbamoyl]oxy}acetate
4		Ethyl 2-{[(naphthalen-1-yl)carbamoyl]oxy}acetate
5		Ethyl 2-{[(2,2-dimethyl-2,3-dihydro-1-benzofuran-7-yl)carbamoyl]oxy}acetate
6		Ethyl 2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-methoxypropanoate
7		Ethyl 2-({[2-fluoro-5-(trifluoromethyl)phenyl]carbamoyl}oxy)acetate







Compound No.	Structure	Name
8		Ethyl 2-{[(2,6-dimethylphenyl)carbamoyl]oxy}acetate
10		Ethyl 2-({[2-(chloro-6-methylphenyl)carbamoyl]oxy}acetate
11		Ethyl 2-{[(2-cyanophenyl)carbamoyl]oxy}acetate
12		Ethyl 2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-(pyridin-3-yl)propanoate
13		Ethyl 2-{[(2-tert-butylphenyl)carbamoyl]oxy}acetate
14		Ethyl 2-((mesitylcarbamoyl)oxy)acetate
15		Ethyl 2-(((2-isopropylphenyl)carbamoyl)oxy)acetate
16		Ethyl 2-(((2-ethyl-6-methylphenyl)carbamoyl)oxy)acetate







Compound No.	Structure	Name
17		Ethyl 2-(((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)oxy)-3-phenylpropanoate
18		Ethyl 2-(((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)oxy)-3-(pyridin-2-yl)propanoate
19		Ethyl (2R)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}propanoate
20		Propan-2-yl 2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}acetate
21		2-{[(1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl]oxy}acetate
22		Cyclopropylmethyl 2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}acetate
23		Cyclobutyl 2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}acetate







Compound No.	Structure	Name
24		2-methylpropyl 2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}acetate
25		Ethyl 3-(4-cyanophenyl)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}propanoate
26		Ethyl 2-({[2-methyl-6-(propan-2-yl)phenyl]carbamoyl}oxy)acetate
27		2-{[(1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl]oxy}acetic acid
28		Ethyl 2-{[(2,6-diethyl-4-methylphenyl)carbamoyl]oxy}acetate
29		Methyl 2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}acetate
30		Ethyl (2R)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-4-phenylbutanoate







Compound No.	Structure	Name
31		Ethyl 2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-(1H-pyrazol-1-yl)propanoate
32		Cyclopentyl 2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}acetate
33		Ethyl 2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-(1H-imidazol-1-yl)propanoate
34		Ethyl 2-({[2,6-bis(propan-2-yl)phenyl]carbamoyl}oxy)acetate
35		Ethyl 2-({[2-chloro-5-(trifluoromethyl)phenyl]carbamoyl}oxy)acetate
36		Ethyl 2-{[(2-tert-butyl-6-methylphenyl)carbamoyl]oxy}acetate
37		Ethyl 2-{[(2,5-dimethylphenyl)carbamoyl]oxy}acetate







Compound No.	Structure	Name
38		2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-methoxypropanoic acid
39		cyclopropyl 2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}acetate
40		2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-(1H-pyrazol-1-yl)propanoic acid
41		Ethyl (2R)-3-(3-cyanophenyl)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}propanoate
42		Ethyl 2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-[3-(1H-pyrazol-1-yl)phenyl]propanoate
43		Ethyl (2R)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-[3-(1H-pyrazol-1-yl)phenyl]propanoate






Compound No.	Structure	Name
44		Ethyl 2-{[(2,6-difluorophenyl)carbamoyl]oxy}-3-1H-pyrazol-1-yl)propanoate
45		Ethyl 2-[(phenylcarbamoyl)oxy]-3-(1H-pyrazol-1-yl)propanoate
46		Ethyl 2-{[(2-ethyl-6-methylphenyl)carbamoyl]oxy}-3-(1H-pyrazol-1-yl)propanoate
47		Ethyl 2-{[(2,6-dimethylphenyl)carbamoyl]oxy}-3-(1H-pyrazol-1-yl)propanoate
48		Ethyl 2-{[(2,6-diethylphenyl)carbamoyl]oxy}-3-(1H-pyrazol-1-yl)propanoate
49		Ethyl 2-{[(2-fluoro-6-methylphenyl)carbamoyl]oxy}-3-(1H-pyrazol-1-yl)propanoate







Compound No.	Structure	Name
50		Ethyl 2-{[(2-chloro-6-fluorophenyl)carbamoyl]oxy}-3-(1H-pyrazol-1-yl)propanoate
51		Ethyl 2-{[(2-chloro-6-methylphenyl)carbamoyl]oxy}-3-(1H-pyrazol-1-yl)propanoate
52		Ethyl 2-{[(2,6-dichlorophenyl)carbamoyl]oxy}-3-(1H-pyrazol-1-yl)propanoate
55		Ethyl 3-(4-cyano-1H-pyrazol-1-yl)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}propanoate
57		Ethyl 2-{[(2-cyano-6-methylphenyl)carbamoyl]oxy}-3-(1H-pyrazol-1-yl)propanoate
58		Ethyl 2-{[(2-cyano-6-ethylphenyl)carbamoyl]oxy}-3-(1H-pyrazol-1-yl)propanoate







Compound No.	Structure	Name
59		Ethyl 2-{[(2-chloro-6-cyanophenyl)carbamoyl]oxy}-3-(1H-pyrazol-1-yl)propanoate
60		Ethyl 2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-(pyrazin-2-yl)propanoate
61		(2R)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-(1H-pyrazol-1-yl)propanoic acid
62		Ethyl 2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-(pyridazin-3-yl)propanoate
63		Ethyl 3-(1H-pyrazol-1-yl)-2-{[(2,3,6-trifluorophenyl)carbamoyl]oxy}propanoate
64		Benzyl (2R)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-(1H-pyrazol-1-yl)propanoate






Compound No.	Structure	Name
65		Ethyl (2R)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-(1H-pyrazol-1-yl)propanoate
66		Ethyl 2-{[(2-ethyl-6-fluorophenyl)carbamoyl]oxy}-3-(1H-pyrazol-1-yl)propanoate
67		Ethyl (2R)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-(1H-imidazol-1-yl)propanoate
68		Ethyl (2R)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-methoxypropanoate
69		(2R)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-methoxypropanoic acid
70		Ethyl 2-({[2-chloro-3-(trifluoromethyl)phenyl]carbamoyl}oxy)-3-(1H-pyrazol-1-yl)propanoate







Compound No.	Structure	Name
71		Ethyl 2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-(1H-1,2,4-triazol-1-yl)propanoate
72		Ethyl 2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-(3-methyl-1H-pyrazol-1-yl)propanoate
73		Ethyl 3-(1H-pyrazol-1-yl)-2-{[(2,4,6-trifluorophenyl)carbamoyl]oxy}propanoate
74		Ethyl 2-({[2-methyl-6-(propan-2-yl)phenyl]carbamoyl}oxy)-3-(1H-pyrazol-1-yl)propanoate
75		Ethyl 2-{[(3-chloro-2,6-difluorophenyl)carbamoyl]oxy}-3-(1H-pyrazol-1-yl)propanoate
76		Ethyl (2R)-3-(4-cyano-1H-pyrazol-1-yl)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}propanoate







Compound No.	Structure	Name
77		Benzyl (2R)-3-(4-cyano-1H-pyrazol-1-yl)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}propanoate
78		Ethyl 2-{[(2,6-dimethylphenyl)carbamoyl]oxy}-3-(pyrimidin-2-yl)propanoate
79		(2R)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-(1H-imidazol-1-yl)propanoic acid
80		Ethyl 3-(4-fluoro-1H-pyrazol-1-yl)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}propanoate
81		Ethyl 2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-(5-methyl-1H-imidazol-1-yl)propanoate







Compound No.	Structure	Name
82		(2R)-3-(4-cyano-1H-pyrazol-1-yl)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}propanoic acid
83		Ethyl (2R)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-(1H-1,2,4-triazol-1-yl)propanoate
84		Ethyl 2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-(2-methyl-1H-imidazol-1-yl)propanoate
85		Ethyl 2-{[(2-chloro-6-ethylphenyl)carbamoyl]oxy}-3-(1H-pyrazol-1-yl)propanoate
86		Ethyl 2-{[(2-methylnaphthalen-1-yl)carbamoyl]oxy}-3-(1H-pyrazol-1-yl)propanoate
88		Ethyl (2R)-3-(4-chloro-1H-pyrazol-1-yl)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}propanoate







Compound No.	Structure	Name
89		Ethyl (2R)-3-(4-cyano-1H-imidazol-1-yl)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}propanoate
90		Ethyl (2R)-3-(5-cyano-1H-imidazol-1-yl)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}propanoate
91		Ethyl 2-({[2,6-dimethyl-4-(trifluoromethyl)phenyl]carbamoyl}oxy)-3-(1H-pyrazol-1-yl)propanoate
92		Ethyl 2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-(4-methoxy-1H-pyrazol-1-yl)propanoate
93		Ethyl (2R)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-(pyrimidin-2-yl)propanoate
94		Ethyl (2R)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-(pyrazin-2-yl)propanoate





Compound No.	Structure	Name
95		Ethyl (2R)-3-ethoxy-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}propanoate
96		Ethyl (2R)-3-(3-cyano-1H-pyrazol-1-yl)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}propanoate
97		Ethyl (2R)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-[4-(trifluoromethyl)-1H-pyrazol-1-yl]propanoate
98		(2R)-3-{4-[(dimethylamino)methyl]-1H-pyrazol-1-yl}-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}propanoic acid hydrochloride
99		Ethyl 2-{[(2,4-dimethylthiophen-3-yl)carbamoyl]oxy}-3-(1H-pyrazol-1-yl)propanoate

Compound No.	Structure	Name
100		Ethyl 2-[({4,10-dioxatricyclo[7.3.0.0^{3,7}]dodeca-1,3(7),8-trien-2-yl}carbamoyl)oxy]-3-(1H-pyrazol-1-yl)propanoate
101		Ethyl (2R)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-(2-methoxyethoxy)propanoate
102		Ethyl (2R)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-(oxan-4-yloxy)propanoate
103		Ethyl (2R)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-(5-methyl-1H-1,2,4-triazol-1-yl)propanoate
104		Ethyl (2R)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-(propan-2-yloxy)propanoate
105		Ethyl (2R)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-(3-methyl-1H-1,2,4-triazol-1-yl)propanoate

Compound No.	Structure	Name
106		(2R)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-(pyrimidin-2-yl)propanoic acid
107		Propan-2-yl (2R)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-(pyrimidin-2-yl)propanoate
108		Cyclopentyl (2R)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-(pyrimidin-2-yl)propanoate
109		(2R)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-(pyrazin-2-yl)propanoic acid
110		Propan-2-yl (2R)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-(pyrazin-2-yl)propanoate
111		Cyclopentyl (2R)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-(pyrazin-2-yl)propanoate

Compound No.	Structure	Name
112		Propan-2-yl (2R)-3-(4-cyano-1H-pyrazol-1-yl)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}propanoate
113		Cyclopentyl (2R)-3-(4-cyano-1H-pyrazol-1-yl)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}propanoate
114		(2R)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-(1H-1,2,4-triazol-1-yl)propanoic acid
115		Propan-2-yl (2R)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-(1H-1,2,4-triazol-1-yl)propanoate
116		Cyclopentyl (2R)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-(1H-1,2,4-triazol-1-yl)propanoate
117		Propan-2-yl 2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-(6-methylpyrazin-2-yl)propanoate

Compound No.	Structure	Name
119		Propan-2-yl 3-(5-cyanopyrazin-2-yl)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}propanoate
120		Propan-2-yl 2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-(2-methylpyrimidin-4-yl)propanoate
121		Propan-2-yl 2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-(5-methylpyrazin-2-yl)propanoate
123		Propan-2-yl 2-{[(2-chloro-6-fluorophenyl)carbamoyl]oxy}-3-(pyrimidin-2-yl)propanoate
124		Propan-2-yl 2-{[(2,6-difluorophenyl)carbamoyl]oxy}-3-(pyrimidin-2-yl)propanoate
125		Propan-2-yl 2-{[(2,6-dichlorophenyl)carbamoyl]oxy}-3-(pyrimidin-2-yl)propanoate

Compound No.	Structure	Name
126		Propan-2-yl (2R)-3-(3-cyano-1H-1,2,4-triazol-1-yl)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}propanoate
127		Propan-2-yl 2-[({bicyclo[2.2.2]octan-1-yl}carbamoyl)oxy]-3-(pyrimidin-2-yl)propanoate
128		Propan-2-yl 2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-(pyridazin-4-yl)propanoate
130		Propan-2-yl 3-(5-cyanopyrimidin-2-yl)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}propanoate.

.

13. A pharmaceutical composition comprising the compound of any one of claims 1-12 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent or carrier.

14. Use of the compound of any one of claims 1-12, or a pharmaceutical salt thereof, or a pharmaceutical composition of claim 13, in the manufacture of a medicament for treating or preventing an autoinflammatory disorder, an autoimmune disorder, a neurodegenerative disease, or cancer.

15. The use of claim 14, wherein the disease or disorder is an autoinflammatory disorder or an autoimmune disorder;

optionally, the disease or disorder is selected from cryopyrin-associated autoinflammatory syndrome (CAPS; e.g., familial cold autoinflammatory syndrome (FCAS)), Muckle-Wells syndrome (MWS), chronic infantile neurological cutaneous and articular (CINCA) syndrome/ neonatal-onset multisystem inflammatory disease (NOMID), familial Mediterranean fever and nonalcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), gout, rheumatoid arthritis, osteoarthritis, Crohn's disease, chronic obstructive pulmonary disease (COPD), chronic kidney disease (CKD), fibrosis, obesity, type 2 diabetes, multiple sclerosis and neuroinflammation occurring in protein misfolding diseases (e.g., Prion diseases).

16. The use of claim 14, wherein disease or disorder is a neurodegenerative disease; optionally, the disease or disorder is Parkinson's disease or Alzheimer's disease.

17. The use of claim 14, wherein the disease or disorder is cancer;

optionally, the cancer is metastasising cancer, gastrointestinal cancer, skin cancer, non-small-cell lung carcinoma, or colorectal adenocarcinoma.